New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
Century Therapeutics presented new preclinical data for CNTY-813 at the ADA 2026 Scientific Sessions, showing durable glucose control for over eight months in diabetic mice. The data confirmed that the Allo-Evasion™ 5.0 engineering allows the islet cells to evade immune rejection in humanized mouse models without the need for chronic immunosuppression.
Key figures
- Drug Name
- CNTY-813
- Cells infused
- >1 billion
- Mice followed
- >140
- G1 phase cells
- >98%
- Beta cell composition
- >50%
- Ind submission target
- 4Q 2026
- Glucose control duration
- >8 months
- Initial clinical data target
- 2H 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.